Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer

被引：22
作者：
Zeng, Yu [1 ,3 ]
Li, Nanhong [2 ,4 ]
Liu, Wang [1 ]
Zeng, Mingqing [5 ]
Cheng, Junfen [1 ]
Huang, Jian [2 ,4 ]
机构：
[1] Guangdong Med Univ, Dept Respirat, Affiliated Hosp 2, 12 Minyou Rd, Zhanjiang 524003, Guangdong, Peoples R China
[2] Guangdong Med Univ, Affiliated Hosp, Pathol Diag & Res Ctr, 57 Renmin Ave South, Zhanjiang 524000, Guangdong, Peoples R China
[3] Guangdong Med Univ, Grad Sch, 2 Wenming Eastern Rd, Zhanjiang 524023, Guangdong, Peoples R China
[4] Guangdong Med Univ, Dept Pathol, 2 Wenming Eastern Rd, Zhanjiang 524023, Guangdong, Peoples R China
[5] Guangdong Med Univ, Clin Sch Med 1, 2 Wenming Eastern Rd, Zhanjiang 524023, Guangdong, Peoples R China
来源：
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2020年 / 146卷 / 10期
基金：
中国国家自然科学基金;
关键词：
Lung cancer; Polo-like kinases; Prognosis; Oncomine; Kaplan-Meier plotter; GENE-EXPRESSION; DNA-DAMAGE; ADENOCARCINOMA; PROTEIN; TARGET; P53; OVEREXPRESSION; INHIBITOR; SNK/PLK2; SURVIVAL;
D O I：
10.1007/s00432-020-03288-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background Despite great advances in its early diagnosis and treatment, lung cancer is still an intractable disease and the second leading cause of cancer-related deaths and morbidity in the world. The family of Polo-like kinases (PLKs) consists of five serine/threonine kinases, which have been reported to participate in various human diseases. However, the expression and prognostic value of each PLK in human lung cancer have not been fully understood. This study analyzed mRNA expression and prognostic value of different PLKs in human non-small cell lung cancer (NSCLC). Methods First, mRNA expression of PLKs in patients with NSCLC from the Oncomine and the Gene Expression Profiling Interactive Analysis (GEPIA) database was investigated. Then, a Kaplan-Meier plotter was employed for survival analysis. The sequence alteration for PLKs was analyzed using The Cancer Genome Atlas (TCGA) and the cBioPortal database. Additionally, we analyzed the association among different PLKs using the LinkedOmics database. Finally, the enrichment analysis of PLKs was achieved using the DAVID database. Results The mRNA expression levels of PLK1 and PLK4 were significantly overexpressed, while mRNA expression level of PLK3 was underexpressed in patients with NSCLC. mRNA expressions of PLK1 and PLK4 were significantly and positively related to the tumor stage of NSCLC. Increased expressions of PLK1, PLK4, and PLK5 and decreased expression of PLK2 were attributed to limited overall survival time in NSCLC. PLK1 was positively correlated with PLK4 via the LinkedOmics database. Conclusions PLKs are relevant targets for NSCLC treatment, especially PLK1 and PLK4.
引用
收藏
页码：2447 / 2460
页数：14
相关论文
共 69 条
[1]   The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus [J].
Andrysik, Zdenek ;
Bernstein, William Z. ;
Deng, Li ;
Myer, David L. ;
Li, Ya-Qin ;
Tischfield, Jay A. ;
Stambrook, Peter J. ;
Bahassi, El Mustapha .
NUCLEIC ACIDS RESEARCH, 2010, 38 (09) :2931-2943
[2]   Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions [J].
Benetatos, Leonidas ;
Dasoula, Aggeliki ;
Hatzimichael, Eleftheria ;
Syed, Nelofer ;
Voukelatou, Maria ;
Dranitsaris, George ;
Bourantas, Konstantinos L. ;
Crook, Tim .
ANNALS OF HEMATOLOGY, 2011, 90 (09) :1037-1045
[3]   Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses [J].
Bhattacharjee, A ;
Richards, WG ;
Staunton, J ;
Li, C ;
Monti, S ;
Vasa, P ;
Ladd, C ;
Beheshti, J ;
Bueno, R ;
Gillette, M ;
Loda, M ;
Weber, G ;
Mark, EJ ;
Lander, ES ;
Wong, W ;
Johnson, BE ;
Golub, TR ;
Sugarbaker, DJ ;
Meyerson, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) :13790-13795
[4]   Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (Taxol)-exposed cells [J].
Burns, TF ;
Fei, PW ;
Scata, KA ;
Dicker, DT ;
El-Deiry, WS .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (16) :5556-5571
[5]   UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses [J].
Chandrashekar, Darshan S. ;
Bashel, Bhuwan ;
Balasubramanya, Sai Akshaya Hodigere ;
Creighton, Chad J. ;
Ponce-Rodriguez, Israel ;
Chakravarthi, Balabhadrapatruni V. S. K. ;
Varambally, Sooryanarayana .
NEOPLASIA, 2017, 19 (08) :649-658
[6]  
Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO
[7]  
2-K
[8]   Plk1 overexpression induces chromosomal instability and suppresses tumor development [J].
de Carcer, Guillermo ;
Venkateswaran, Sharavan Vishaan ;
Salgueiro, Lorena ;
El Bakkali, Aicha ;
Somogyi, Kalman ;
Rowald, Konstantina ;
Montanes, Pablo ;
Sanclemente, Manuel ;
Escobar, Beatriz ;
de Martino, Alba ;
McGranahan, Nicholas ;
Malumbres, Marcos ;
Sotillo, Rocio .
NATURE COMMUNICATIONS, 2018, 9
[9]   Plk5, a Polo Box Domain-Only Protein with Specific Roles in Neuron Differentiation and Glioblastoma Suppression [J].
de Carcer, Guillermo ;
Escobar, Beatriz ;
Higuero, Alonso M. ;
Garcia, Laura ;
Anson, Alejandra ;
Perez, Gema ;
Mollejo, Manuela ;
Manning, Gerard ;
Melendez, Barbara ;
Abad-Rodriguez, Jose ;
Malumbres, Marcos .
MOLECULAR AND CELLULAR BIOLOGY, 2011, 31 (06) :1225-1239
[10]   Mutant p53 as a target for cancer treatment [J].
Duffy, Michael J. ;
Synnott, Naoise C. ;
Crown, John .
EUROPEAN JOURNAL OF CANCER, 2017, 83 :258-265
1234567